Camurus' Oczyesa Receives Positive CHMP Opinion For Acromegaly Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2025
0mins
Source: NASDAQ.COM
Positive Opinion for Oczyesa: The European Medicines Agency's Committee has recommended market authorization for Camurus' Oczyesa, an octreotide subcutaneous depot for treating adults with acromegaly who have previously responded to somatostatin analogues.
Clinical Trial Support: The recommendation is backed by a comprehensive clinical program showing significant benefits in managing the condition, with a final decision from the European Commission expected by mid-2025.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
